Bora Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility
Exhibitor: BORA PHARMACEUTICALS CO., LTD.
Date: 2024-07-03
Booth No.: M212
Acquisition of Emergent BioSolutions’ sterile manufacturing facility in Camden, Maryland will allow Bora to provide Sterile Fill/Finish Services.
Taipei, Taiwan, June 20, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that it has successfully entered into an agreement for Emergent BioSolutions’ (“Emergent”, NYSE: EBS) sterile manufacturing facility in Baltimore-Camden, Maryland as part of a major commercial expansion for the Company.
Bora has an established footprint in the US following its acquisition of Upsher-Smith Laboratories, a generics manufacturer based in Minnesota, earlier this year. This second acquisition is the next milestone in the Company’s growth strategy, as it continues its plans to expand into sterile drug product manufacturing and grow its footprint in North America.
The newly acquired 87,000-sq. ft. facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, vials filling and pre-filled syringe filling.
This acquisition will allow Bora to offer drug substance and drug product capabilities, and complements the services of Bora Biologics, the Company’s development and manufacturing offering for biologics developers.
Commenting on this latest acquisition, Bobby Sheng, Chairman and CEO of Bora Group said: “This transaction not only demonstrates our commitment to our growth strategy and plans for expansion in North America, but also enables us to expand our offering for our biologics customers. We look forward to working with the hugely talented team at the facility and supporting new and existing customers as we grow and develop the facility.”
The sterile injectable market continues to grow and the market size is expected to reach approximately $1.0 trillion by 2030 at a 6-year CAGR of 10.17%, according to researchandmarkets. Bora has ambitious plans to enhance the newly acquired facility, and all staff currently based at the Camden site will be given the opportunity to remain in place and become part of the Bora team.
Gibson Dunn advised Bora on the transaction.
About Bora:
Founded in 2007, Bora Pharmaceutical Co., Ltd. (“Bora” or “the Company”, 6472.TW) is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Bora is dedicated to becoming a global leader in pharmaceutical manufacturing by offering its clients the best quality, efficiency, and reliability. For more information, visit www.bora-corp.com.
More Exhibitor's Press Release
- Taiwan’s Regenerative Medicine Acts passed, MYCENAX CDMO Services Are Ready! MYCENAX BIOTECH INC. / 2024-07-08
- Registration Today! 2024 BIO Asia Taiwan. Golden Biotech Seminar Registration GOLDEN BIOTECHNOLOGY CORP. / 2024-07-06
- EffPha meets you at BIO Asia- Taiwan Exhibition 2024 EFFICIENT PHARMA MANAGEMENT CORP. / 2024-07-05
- EffPha – An expert-based CRO for your drug development EFFICIENT PHARMA MANAGEMENT CORP. / 2024-07-05
- Featured Product: Saltonase, the Versatile Nuclease - Salt Tolerant and Easier Purification QIAGEN N.V. / 2024-07-05
- Vega Preclinical Ultrasound System J & H TECHNOLOGY CO., LTD. / 2024-07-05
- MYCENAX,YOUR BEST PARTNER FOR BIOLOGICS DEVELOPMENT MYCENAX BIOTECH INC. / 2024-07-04
- Application and Market Development of Foods with Functional Claims in Japan GREENLINK BIOTECH INC. / 2024-07-03
- Featured Product: QIAGEN Beverly Single-Tube Enzymatic Fragmentation Library Preparation QIAGEN N.V. / 2024-07-02
- OEM by QIAGEN: Strategic Partnerships – A Partner that Extends Your Capabilities QIAGEN N.V. / 2024-07-02
- Comparison of Maglev Centrifugal Pump and Quaternary Diaphragm Pump Effects on mRNA encapsulated LNP LEVITRONIX GMBH TAIWAN BRANCH / 2024-07-01
- CRISPR cGMP gRNA Manufacturing MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- High-Throughput NGS Assistant - Feyond-F100 Fluorescence Microplate Reader MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- CLUBIO Life science solutions help universities upgrade equipments MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- EDA providing the most advanced and innovative optoelectronic medical equipment. EDA MEDICAL DEVICES TECHNOLOGY INC. / 2024-06-25
- TaiMed Biologics: Comprehensive CDMO Services from Bench to Market TAIMED BIOLOGICS INC. / 2024-06-25
- Marker X Decodes the Cancer Proteome Breaking the Limits of Early Cancer Screening Globally! MARKER EXPLORATION CORP. / 2024-06-21
- EffPha is the leading CRO for early phase oncology trials EFFICIENT PHARMA MANAGEMENT CORP. / 2024-06-20
- FUJIFILM Toyama Chemical and Synplogen Enter Strategic Business Alliance Agreement on CDMO Services FUJIFILM CORPORATION / 2024-06-18
- TriLink BioTechnologies® and FUJIFILM Toyama Chemical Sign Non-exclusive License FUJIFILM CORPORATION / 2024-06-18